Ligand ID: IL2 Drugbank ID: DB01088(Iloprost) Indication:Used for the treatment of pulmonary arterial hypertension. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 1wnc | E2 GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | THR E 922THR E 921LEU F 920VAL F1170ILE E 916 | 1.64A | 20.65 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 1wof | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH B 117THR A 304SER B 123VAL B 114TYR B 126 | 1.75A | 23.44 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 1z1i | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | LEU A 75THR A 21THR A 25VAL A 77HIS A 41 | 1.63A | 23.56 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 1z1j | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH A 117THR B1304SER A 123VAL A 114TYR A 126 | 1.75A | 22.15 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 2a5k | 3C-LIKE PEPTIDASE (SARSr-CoV) | 5 / 12 | CYH B 117THR A 304SER B 123VAL B 114TYR B 126 | 1.77A | 21.85 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 2acf | REPLICASEPOLYPROTEIN 1AB (SARS-COVTor2) | 5 / 12 | LEU D 319HIS A 227LEU A 253VAL D 347HIS A 276 | 1.55A | 21.71 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 2cme | HYPOTHETICAL PROTEIN5 (SARSr-CoV) | 5 / 12 | VAL A 16THR A 23ILE A 24LEU B 55VAL A 95 | 1.56A | 15.75 | NoneNoneNoneD10 B1099 ( 4.6A)D10 B1099 ( 4.8A) | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 2fav | REPLICASEPOLYPROTEIN 1AB(PP1AB) (ORF1AB) (SARSr-CoV) | 5 / 12 | PHE C 117CYH C 144SER C 140ILE C 154VAL C 37 | 1.78A | 22.81 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 2fe8 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | THR A 198TYR C 269ILE A 223VAL A 221TYR A 208 | 1.78A | 20.17 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 2fe8 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | LEU C 121CYH C 149HIS C 90VAL C 117ILE C 105 | 1.62A | 19.94 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 2ga6 | ORF1A POLYPROTEIN (SARSr-CoV) | 5 / 12 | PHE U 19HIS U 80ILE Q 81VAL X 21ILE X 81 | 1.59A | 20.07 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 2k87 | NSP3 OF REPLICASEPOLYPROTEIN 1A (SARSr) | 5 / 12 | LEU A 108THR A 97ILE A 89VAL A 52ILE A 65 | 1.39A | 17.02 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 2xyq | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | PHE A 193CYH A 51SER A 243VAL A 44VAL A 9 | 1.68A | 20.83 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 2xyr | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | PHE A 193CYH A 51SER A 243VAL A 44VAL A 9 | 1.67A | 20.83 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 2z9l | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH B 117THR A 304SER B 123VAL B 114TYR B 126 | 1.73A | 22.15 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 3atw | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH B 22THR B 24THR B 25ILE B 43HIS B 41 | 1.46A | 23.58 | NoneNoneNoneNoneALC D 4 ( 3.9A) | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 3d0i | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | VAL B 404PHE B 400THR B 519THR B 517ILE B 513 | 1.56A | 19.06 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 3d0i | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | LEU B 156THR B 282ILE B 256HIS B 241TYR B 237 | 1.66A | 19.06 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 3e9s | NSP3 (SARSr-CoV) | 5 / 12 | LEU A 121CYH A 149HIS A 90VAL A 117ILE A 105 | 1.64A | 20.60 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 3ea7 | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH B 117THR A 304SER B 123VAL B 114TYR B 126 | 1.78A | 22.49 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 3f9e | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH A 22THR A 24THR A 25ILE A 43HIS A 41 | 1.47A | 23.42 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 3f9g | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH B 22THR B 24THR B 25ILE B 43HIS B 41 | 1.63A | 22.26 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 3m3s | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH B 117THR A 304SER B 123VAL B 114TYR B 126 | 1.77A | 22.15 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 3r24 | 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | PHE A 193CYH A 51SER A 243VAL A 44VAL A 9 | 1.69A | 23.10 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 3scj | ACE2 (Homosapiens) | 5 / 12 | VAL B 404PHE B 400THR B 519THR B 517ILE B 513 | 1.54A | 19.23 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 3scj | ACE2 (Homosapiens) | 5 / 12 | LEU B 281THR B 445ILE B 446LEU B 240VAL B 244 | 1.62A | 19.23 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 3scl | ACE2 (Pagumalarvata;Homosapiens;SARSr-CoV) | 5 / 12 | LEU B 156THR B 282ILE B 256HIS B 241TYR B 237 | 1.66A | 19.06 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 4hi3 | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH A 22THR A 24THR A 25ILE A 43HIS A 41 | 1.53A | 21.07 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 4m0w | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 5 / 12 | LEU A 121CYH A 149HIS A 90VAL A 117ILE A 105 | 1.65A | 21.14 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 4mds | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | CYH A 22THR A 24THR A 25ILE A 43HIS A 41 | 1.53A | 23.17 | DMS A 402 (-3.9A)DMS A 402 (-4.2A)DMS A 402 (-4.4A)None23H A 401 (-3.7A) | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 4ovz | PAPAIN-LIKEPROTEINASE (SARS-COVUrbani) | 5 / 12 | LEU A 121CYH A 149HIS A 90VAL A 117ILE A 105 | 1.66A | 20.72 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 5c8u | GUANINE-N7METHYLTRANSFERASENSP10 (SARSr-CoV) | 5 / 12 | CYH C 41THR D 25SER D 28VAL C 7TYR D 51 | 1.77A | 19.71 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 5c8u | GUANINE-N7METHYLTRANSFERASENSP10 (SARSr-CoV) | 5 / 12 | THR B 25SER B 28VAL A 7ILE B 55TYR B 51 | 1.73A | 19.85 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5e6j | POLYUBIQUITIN-BREPLICASEPOLYPROTEIN 1AB (SARSr-CoV;syntheticconstruct) | 5 / 12 | LEU F 50THR F 12HIS A 18LEU F 15VAL F 26 | 1.38A | 17.34 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5e6j | POLYUBIQUITIN-BREPLICASEPOLYPROTEIN 1AB (SARSr-CoV;syntheticconstruct) | 5 / 12 | LEU C 50THR C 12HIS D 18VAL C 26ILE C 3 | 1.28A | 17.34 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5e6j | POLYUBIQUITIN-BREPLICASEPOLYPROTEIN 1AB (SARSr-CoV;syntheticconstruct) | 5 / 12 | LEU D 81VAL D 58PHE D 32THR D 19ILE C 13 | 1.43A | 21.43 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 5e6j | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | PHE D 305CYH D 261THR D 278VAL D 166TYR D 274 | 1.72A | 20.44 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 5nfy | POLYPROTEIN 1AB (SARS-COVFrankfurt1) | 5 / 12 | THR D 25SER D 28VAL O 7ILE D 55TYR D 51 | 1.79A | 20.97 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 91THR A 98LEU A 30VAL A 18 | 1.77A | 19.19 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.72A | 19.19 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5tl6 | REPLICASEPOLYPROTEIN 1AB (SARSr-CoV) | 5 / 12 | LEU D 121CYH D 149HIS D 90VAL D 117ILE D 105 | 1.65A | 20.54 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5x5b | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 12 | THR A 925THR A 923LEU A 804VAL A1043ILE A 916 | 1.51A | 12.24 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5x5b | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 12 | LEU B 745VAL B 990THR B 943LEU B 840VAL B 718 | 1.07A | 12.24 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5xlr | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU A1045PHE A 799THR A 921LEU A 927VAL A1043 | 1.44A | 12.75 | LEU A1045 ( 0.6A)PHE A 799 ( 1.3A)THR A 921 ( 0.8A)LEU A 927 ( 0.6A)VAL A1043 ( 0.6A) | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5xlr | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU C 745VAL C 990THR C 943LEU C 840VAL C 718 | 1.05A | 12.75 | LEU C 745 ( 0.5A)VAL C 990 ( 0.6A)THR C 943 ( 0.8A)LEU C 840 ( 0.6A)VAL C 718 ( 0.6A) | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 5y3e | REPLICASEPOLYPROTEIN 1A (SARSr-CoV) | 5 / 12 | LEU A 121CYH A 149HIS A 90VAL A 117ILE A 105 | 1.65A | 19.94 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6acg | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | THR B 20LEU B 132VAL B 102ILE B 152HIS B 149 | 1.45A | 12.75 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6acg | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU A 745VAL A 990THR A 943LEU A 840VAL A 718 | 0.94A | 12.75 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6acj | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | CYH A 19CYH A 133THR A 21ILE A 152VAL A 102 | 1.58A | 12.55 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6crv | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | LEU A 286LEU A 636VAL A 596ILE A 674HIS A 661 | 1.56A | 12.16 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6crv | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | LEU B 745VAL B 990THR B 943LEU B 840VAL B 718 | 1.08A | 12.16 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6crv | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | PHE A 62THR A 34SER A 35TYR A 88VAL A 40 | 1.53A | 12.92 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6crz | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | PHE C 62THR C 34SER C 35TYR C 88VAL C 40 | 1.57A | 12.92 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6crz | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | LEU B 745VAL B 990THR B 943LEU B 840VAL B 718 | 0.97A | 12.52 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6cs0 | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | THR A 923THR A 922LEU A 804VAL A1043ILE A 916 | 1.29A | 12.52 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6jyt | HELICASE (SARSr-CoV) | 5 / 12 | LEU B 384CYH B 309THR B 307ILE B 333VAL B 386 | 1.61A | 19.40 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6jyt | HELICASE (SARSr-CoV) | 5 / 12 | CYH B 26CYH B 27THR B 12SER B 13TYR B 48 | 1.78A | 20.49 | ZN B 701 (-2.3A)NoneNoneNoneNone | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | CYH A 22THR A 24THR A 25ILE A 43HIS A 41 | 1.49A | 21.05 | NoneNoneNoneNoneALC D 2 ( 4.1A) | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.67A | 21.05 | DMS A 403 ( 4.9A)ALC D 2 ( 4.1A)NoneNoneNone | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6lzg | ACE2 (Homosapiens) | 5 / 12 | LEU A 248THR A 445ILE A 446LEU A 240VAL A 244 | 1.63A | 19.23 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.68A | 21.60 | DMS A 401 ( 4.8A)N0A D 2 ( 4.0A)NoneNoneNone | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | CYH A 22THR A 24THR A 25ILE A 43HIS A 41 | 1.51A | 21.60 | NoneNoneNoneNoneN0A D 2 ( 4.0A) | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m1d | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 5 / 12 | LEU A 77VAL A 275PHE A 277LEU A 269TYR A 128 | 1.50A | 17.71 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m1d | ACE2 (Homosapiens) | 5 / 12 | LEU B 584THR B 517HIS B 401HIS B 378TYR B 381 | 1.57A | 15.68 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL C 18HIS C 41LEU C 89VAL C 91HIS C 164 | 1.70A | 21.47 | None3WL C 401 (-3.4A)NoneNoneNone | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL B 18HIS B 41LEU B 89VAL B 91HIS B 164 | 1.67A | 21.47 | None3WL B 401 (-3.7A)NoneNoneNone | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | CYH A 117THR C 304SER A 123VAL A 114TYR A 126 | 1.78A | 22.89 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.64A | 21.47 | None3WL A 401 (-3.7A)NoneNoneNone | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL D 18HIS D 41LEU D 89VAL D 91HIS D 164 | 1.72A | 21.47 | None3WL D 401 (-3.9A)NoneNoneNone | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 18ILE A 43LEU A 89VAL A 91HIS A 41 | 1.79A | 21.47 | NoneNoneNoneNone3WL A 401 (-3.7A) | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | CYH C 22THR C 24THR C 25ILE C 43HIS C 41 | 1.55A | 21.47 | NoneNoneNoneNone3WL C 401 (-3.4A) | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 91THR A 98LEU A 30VAL A 18 | 1.77A | 21.47 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.73A | 21.47 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 187PHE A 283HIS A 309ILE A 466LEU A 245 | 1.57A | 15.69 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 308PHE A 694THR A 680LEU A 638VAL A 637 | 1.75A | 15.69 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 373PHE A 506CYH A 563THR A 567THR A 565 | 1.79A | 15.69 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 207THR A 248LEU A 131VAL A 128ILE A 145 | 1.57A | 15.69 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 308PHE A 694THR A 680LEU A 638VAL A 637 | 1.77A | 15.69 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 638VAL A 693PHE A 694THR A 701LEU A 308 | 1.72A | 15.69 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | THR A 710SER A 709VAL A 720VAL A 785TYR A 788 | 1.75A | 16.30 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m71 | NSP12NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 98PHE A 429ILE A 548LEU C 40TYR A 884 | 1.56A | 21.58 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 187PHE A 283HIS A 309ILE A 466LEU A 245 | 1.59A | 15.69 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 694CYH A 697THR A 701VAL A 475MET A 633 | 1.78A | 16.30 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6m71 | NSP12NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 98PHE A 429ILE A 548LEU C 40TYR A 884 | 1.52A | 21.58 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6nb6 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU C1045PHE C 799THR C 921LEU C 927VAL C1043 | 1.36A | 12.21 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6nb6 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | LEU B 745VAL B 990THR B 943LEU B 840VAL B 718 | 1.11A | 12.21 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6nur | NSP12NSP7NSP8 (SARSr-CoV) | 5 / 12 | LEU D 98PHE A 429ILE A 548LEU C 40TYR A 884 | 1.32A | 22.11 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6nur | NSP12NSP7NSP8 (SARSr-CoV) | 5 / 12 | LEU D 98PHE A 429ILE A 548LEU C 40TYR A 884 | 1.28A | 22.11 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6nur | NSP12 (SARSr-CoV) | 5 / 12 | VAL A 693PHE A 694CYH A 697THR A 701VAL A 637 | 1.54A | 15.31 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6nus | NSP12 (SARSr-CoV) | 5 / 12 | LEU A 207THR A 248LEU A 131VAL A 128ILE A 145 | 1.56A | 15.31 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6nus | NSP12 (SARSr-CoV) | 5 / 12 | PHE A 480CYH A 482THR A 582ILE A 757TYR A 689 | 1.78A | 15.99 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU A1004THR A 734THR A 732HIS A1058VAL A1008 | 1.65A | 11.33 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE A 906THR A1066VAL A 722ILE A 923VAL A 915 | 1.76A | 13.00 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU C 763VAL C1008THR C 961LEU C 858VAL C 736 | 1.05A | 11.33 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6vw1 | ACE2 (Homosapiens) | 5 / 12 | VAL A 404PHE A 400THR A 519THR A 517ILE A 513 | 1.52A | 19.23 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | VAL B 147ILE B 137LEU B 153VAL B 151HIS B 138 | 1.21A | None | |||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | PHE B 168SER B 139TYR B 113ILE B 18VAL B 16 | 1.74A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6vxs | NSP3 (SARS-CoV-2) | 5 / 12 | VAL A 147ILE A 137LEU A 153VAL A 151HIS A 138 | 1.25A | None | |||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE B 906THR B1066VAL B 722ILE B 923VAL B 915 | 1.63A | 12.48 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU A 763VAL A1008THR A 961LEU A 858VAL A 736 | 1.20A | 11.54 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE A 906THR A1066VAL A 722ILE A 923VAL A 915 | 1.61A | 12.48 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | PHE A 92ILE A 235LEU A 229VAL A 227ILE A 119 | 1.65A | 11.54 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU A 763VAL A1008THR A 961LEU A 858VAL A 736 | 1.16A | 11.54 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w4h | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6991CYH A6849SER A7041VAL A6842VAL A6807 | 1.66A | 21.36 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6991CYH A6849SER A7041VAL A6842VAL A6807 | 1.67A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.69A | NoneX77 A 401 (-3.2A)NoneNoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | VAL B 147ILE B 137LEU B 153VAL B 151HIS B 138 | 1.35A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w6y | NSP3 (SARS-CoV-2) | 5 / 12 | VAL A 147ILE A 137LEU A 153VAL A 151HIS A 138 | 1.33A | None | |||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6991CYH A6849SER A7041VAL A6842VAL A6807 | 1.67A | 22.18 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | PHE C6991CYH C6849SER C7041VAL C6842VAL C6807 | 1.66A | 22.18 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6892VAL C7094THR A6918LEU A6909VAL A6894 | 1.65A | 19.79 | NoneNoneFMT A7109 ( 4.5A)NoneNone | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892VAL C7086LEU C6909VAL C6894HIS A6917 | 1.72A | 19.79 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6892VAL A7086LEU A6909VAL A6894HIS C6917 | 1.62A | 19.79 | NoneNoneNoneNoneFMT C7113 ( 4.9A) | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892VAL A7094THR C6918LEU C6909VAL C6894 | 1.76A | 19.79 | NoneNoneFMT C7113 ( 4.8A)NoneNone | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892VAL A7094THR A6915LEU C6909VAL C6894 | 1.71A | 19.79 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6892VAL C7094THR C6915LEU A6909VAL A6894 | 1.50A | 19.79 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | LEU C 290VAL C 98THR C 115ILE C 151TYR C 136 | 1.73A | None | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE C 304CYH C 260THR C 277ILE C 285ILE C 123 | 1.61A | 20.48 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | PHE A 304CYH A 260THR A 277ILE A 285ILE A 123 | 1.79A | 20.48 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wcf | NSP3 (SARS-CoV-2) | 5 / 12 | VAL A 147ILE A 137LEU A 153VAL A 151HIS A 138 | 1.32A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wen | NSP3 (SARS-CoV-2) | 5 / 12 | VAL A 147ILE A 137LEU A 153VAL A 151HIS A 138 | 1.40A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wey | NSP3 (SARS-CoV-2) | 5 / 12 | VAL A 351ILE A 341LEU A 357VAL A 355HIS A 342 | 1.34A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU C6892VAL A7094THR A6915LEU C6909VAL C6894 | 1.67A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU C6892VAL A7094THR C6918LEU C6909VAL C6894 | 1.71A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A6892VAL C7094THR C6915LEU A6909VAL A6894 | 1.52A | NoneNoneFMT C7107 (-3.7A)NoneNone | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A6892THR A6918HIS C6917LEU A6909VAL A6894 | 1.59A | 21.04 | None | ||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6991CYH A6849SER A7041VAL A6842VAL A6807 | 1.66A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU A6892VAL A7086HIS C6917LEU A6909VAL A6894 | 1.56A | None | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | ILE A7079LEU A6892VAL C7094ILE A6866TYR A7009 | 1.57A | 21.04 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | VAL A7094THR C6918HIS A6917LEU C6909VAL C6894 | 1.68A | None | |||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE C6991CYH C6849SER C7041VAL C6842VAL C6807 | 1.66A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | LEU C6892VAL C7086LEU C6909VAL C6894HIS A6917 | 1.63A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6892VAL C7094THR C6915LEU A6909VAL A6894 | 1.59A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6892VAL C7094THR A6918LEU A6909VAL A6894 | 1.67A | NoneNoneFMT A7108 ( 4.8A)NoneNone | |||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | PHE C6991CYH C6849SER C7041VAL C6842VAL C6807 | 1.66A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892VAL A7094THR A6915LEU C6909VAL C6894 | 1.65A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6892VAL A7086LEU A6909VAL A6894HIS C6917 | 1.66A | NoneNoneNoneNoneFMT C7108 ( 4.7A) | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | VAL C7094THR A6918HIS C6917LEU A6909VAL A6894 | 1.69A | NoneFMT A7108 ( 4.8A)FMT C7108 ( 4.7A)NoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892VAL C7086LEU C6909VAL C6894HIS A6917 | 1.65A | None | |||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | PHE A6991CYH A6849SER A7041VAL A6842VAL A6807 | 1.66A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | VAL A7094THR C6918HIS A6917LEU C6909VAL C6894 | 1.73A | NoneFMT C7108 ( 4.9A)NoneNoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wkq | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892VAL A7094THR C6918LEU C6909VAL C6894 | 1.69A | NoneNoneFMT C7108 ( 4.9A)NoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.64A | NoneU5G A 401 (-3.3A)NoneNoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL D 147ILE D 137LEU D 153VAL D 151HIS D 138 | 1.34A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 147ILE A 137LEU A 153VAL A 151HIS A 138 | 1.37A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL C 49PHE C 156ILE C 18LEU C 123VAL C 35 | 1.71A | APR C 201 (-3.8A)APR C 201 (-4.7A)NoneNoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL B 49PHE B 156ILE B 18LEU B 123VAL B 35 | 1.73A | APR B 201 (-3.7A)APR B 201 (-4.6A)NoneNoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL C 147ILE C 137LEU C 153VAL C 151HIS C 138 | 1.33A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL D 49PHE D 156ILE D 18LEU D 123VAL D 35 | 1.75A | APR D 201 (-3.6A)APR D 201 (-4.5A)NoneNoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL B 147ILE B 137LEU B 153VAL B 151HIS B 138 | 1.40A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6woj | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 49PHE A 156ILE A 18LEU A 123VAL A 35 | 1.73A | APR A 201 (-3.8A)APR A 201 (-4.7A)NoneNoneNone | |||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 5 / 12 | PHE A6991CYH A6849SER A7041VAL A6842VAL A6807 | 1.64A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 18ILE A 43LEU A 89VAL A 91HIS A 41 | 1.78A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.69A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 68THR A 25VAL A 77HIS A 41 | 1.80A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 91THR A 98LEU A 30VAL A 18 | 1.75A | 19.93 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.72A | 19.93 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | LEU B 81LEU B 45VAL B 37ILE B 93TYR B 180 | 1.77A | 19.86 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | LEU H 18THR B 9THR B 113ILE B 20VAL H 11 | 1.76A | NoneMLI B 304 (-4.0A)NoneNoneNone | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yla | HEAVY CHAINLIGHT CHAIN (Homosapiens) | 5 / 12 | LEU C 52THR B 31ILE B 30LEU B 4VAL B 108 | 1.76A | 21.36 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yla | HEAVY CHAIN (Homosapiens) | 5 / 12 | LEU B 18THR H 9THR H 113ILE H 20VAL B 11 | 1.78A | NoneNoneNoneNoneDMS H 303 ( 4.6A) | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yla | HEAVY CHAINLIGHT CHAIN (Homosapiens) | 5 / 12 | LEU C 52THR B 31ILE B 30LEU B 4VAL B 108 | 1.71A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yla | HEAVY CHAINLIGHT CHAIN (Homosapiens) | 5 / 12 | LEU L 52THR H 31ILE H 30LEU H 4VAL H 108 | 1.67A | None | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yla | HEAVY CHAINLIGHT CHAIN (Homosapiens) | 5 / 12 | LEU L 52THR H 31ILE H 30LEU H 4VAL H 108 | 1.71A | 21.36 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ym0 | HEAVY CHAINLIGHT CHAIN (Homosapiens) | 5 / 12 | LEU L 52THR H 31ILE H 30LEU H 4VAL H 108 | 1.67A | 21.36 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ym0 | HEAVY CHAINLIGHT CHAIN (Homosapiens) | 5 / 12 | LEU L 52THR H 31ILE H 30LEU H 4VAL H 108 | 1.63A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.72A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 91THR A 98LEU A 30VAL A 18 | 1.74A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yor | IGG H CHAINIGG L CHAIN (Homosapiens) | 5 / 12 | LEU L 52THR H 31ILE H 30LEU H 4VAL H 108 | 1.66A | None | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yor | IGG H CHAINIGG L CHAIN (Homosapiens) | 5 / 12 | LEU C 52THR B 31ILE B 30LEU B 4VAL B 108 | 1.71A | 21.36 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yor | IGG H CHAINIGG L CHAIN (Homosapiens) | 5 / 12 | LEU L 52THR H 31ILE H 30LEU H 4VAL H 108 | 1.70A | 21.36 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yor | IGG H CHAINIGG L CHAIN (Homosapiens) | 5 / 12 | LEU C 52THR B 31ILE B 30LEU B 4VAL B 108 | 1.67A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.75A | NonePK8 A 401 (-3.2A)NoneNoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 91THR A 98LEU A 30VAL A 18 | 1.78A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL C 147ILE C 137LEU C 153VAL C 151HIS C 138 | 1.29A | NoneNoneNoneNoneEDO C 208 ( 4.9A) | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL E 147ILE E 137LEU E 153VAL E 151HIS E 138 | 1.37A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL B 147ILE B 137LEU B 153VAL B 151HIS B 138 | 1.28A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL D 147ILE D 137LEU D 153VAL D 151HIS D 138 | 1.33A | NoneNoneNoneNoneEDO D 204 (-4.1A) | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywk | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL A 147ILE A 137LEU A 153VAL A 151HIS A 138 | 1.32A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL C 147ILE C 137LEU C 153VAL C 151HIS C 138 | 1.28A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL A 147ILE A 137LEU A 153VAL A 151HIS A 138 | 1.29A | NoneNoneNoneNoneEDO A 204 ( 4.0A) | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL D 147ILE D 137LEU D 153VAL D 151HIS D 138 | 1.31A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL B 147ILE B 137LEU B 153VAL B 151HIS B 138 | 1.27A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywl | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL E 147ILE E 137LEU E 153VAL E 151HIS E 138 | 1.39A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL C 147ILE C 137LEU C 153VAL C 151HIS C 138 | 1.33A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL A 147ILE A 137LEU A 153VAL A 151HIS A 138 | 1.31A | NoneEDO A 206 (-4.6A)NoneNoneEDO A 205 (-3.9A) | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 6ywm | NSP3 MACRODOMAIN (SARS-CoV-2) | 5 / 12 | VAL B 147ILE B 137LEU B 153VAL B 151HIS B 138 | 1.32A | NoneNoneNoneNoneEDO B 204 ( 4.6A) | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.69A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 18ILE A 43LEU A 89VAL A 91HIS A 41 | 1.79A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | LEU A 75VAL A 68THR A 25VAL A 77HIS A 41 | 1.75A | None | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 98PHE A 429ILE A 548LEU C 40TYR A 884 | 1.53A | 21.58 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 373PHE A 506CYH A 563THR A 567THR A 565 | 1.58A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 98PHE A 429ILE A 548LEU C 40TYR A 884 | 1.49A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | PHE A 843CYH C 8THR C 9HIS C 36ILE C 39 | 1.62A | None | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 308PHE A 694THR A 680LEU A 638VAL A 637 | 1.72A | 15.69 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 638VAL A 693PHE A 694THR A 701LEU A 308 | 1.74A | None | |||
![]() | 3SP6_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | PHE A 694CYH A 697THR A 701VAL A 475MET A 633 | 1.77A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 308PHE A 694THR A 680LEU A 638VAL A 637 | 1.69A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 693PHE A 694CYH A 697THR A 701LEU A 308 | 1.64A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 184VAL B 159THR B 146LEU B 128VAL B 130 | 1.79A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 693PHE A 694CYH A 697THR A 701LEU A 469 | 1.74A | None | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | PHE A 843CYH C 8THR C 9HIS C 36ILE C 39 | 1.64A | 15.69 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 693PHE A 694CYH A 697THR A 701VAL A 637 | 1.44A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | VAL A 18HIS A 41LEU A 89VAL A 91HIS A 164 | 1.69A | DMS A 403 ( 4.9A)JRY A 401 (-3.9A)NoneNoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv1 | NSP12NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 98PHE A 429ILE A 548LEU C 40TYR A 884 | 1.37A | None | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv1 | NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 169CYH D 142THR D 141THR D 148ILE D 156 | 1.61A | 20.14 | None | ||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv1 | NSP12NSP7NSP8 (SARS-CoV-2) | 5 / 12 | LEU D 98PHE A 429ILE A 548LEU C 40TYR A 884 | 1.41A | 20.14 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 638VAL A 693PHE A 694THR A 701LEU A 308 | 1.72A | None | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 308PHE A 694THR A 680LEU A 638VAL A 637 | 1.78A | 15.67 | None | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv1 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | PHE A 843CYH C 8THR C 9HIS C 36ILE C 39 | 1.77A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 308PHE A 694THR A 680LEU A 638VAL A 637 | 1.76A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 693PHE A 694CYH A 697THR A 701LEU A 469 | 1.73A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 373PHE A 506CYH A 563THR A 567THR A 565 | 1.75A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 373PHE A 506CYH A 563THR A 567THR A 565 | 1.74A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 693PHE A 694CYH A 697THR A 701LEU A 308 | 1.64A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 693PHE A 694CYH A 697THR A 701VAL A 637 | 1.41A | None | |||
![]() | 3SP9_A_IL2A901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 308PHE A 694THR A 680LEU A 638VAL A 637 | 1.80A | 15.67 | NoneNoneF86 P 102 ( 4.9A)NoneNone | ||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 308PHE A 694THR A 680LEU A 638VAL A 637 | 1.77A | NoneNoneF86 P 102 ( 4.9A)NoneNone | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | LEU A 638VAL A 693PHE A 694THR A 701LEU A 308 | 1.79A | None | |||
![]() | 3SP9_B_IL2B901_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR DELTA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | VAL A 693PHE A 694CYH A 697THR A 701LEU A 469 | 1.78A | None |